Valrubicin
Valrubicin ("N"-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues. Valstar was relaunched on September 3, 2009.
Q974135
chemotherapy
Concept
Q12140
drug
Concept
Q504775
bladder cancer
Concept
Q417589
anthracycline
Concept
Q18936
doxorubicin
Concept
Q9382
bladder
Concept
Q9382
intravesical
Concept
Q798309
Bacille Calmette-Guérin
Concept
Q1035645
carcinoma in situ
Concept
Q9382
urinary bladder
Concept
Q245995
cystectomy
UNK
Q12136
morbidity
Concept
Q58702
mortality
Concept
Q7912593
Valrubicin
Concept
Q7912593
Valrubicin
Concept
1999-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1999
DATE
2002-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2002
DATE
2009-09-03T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
September 3, 2009
DATE
-14^^http://www.w3.org/2001/XMLSchema#decimal
-14
NUMBER
instance of
medical condition treated
subclass of